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ther studies in patients with CRF are necessary to define theEfficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treat-
clinical applicability of 19-Nor on bone histology in humans.ment of hyperparathyroid bone disease in experimental uremia.
Background. The control of parathyroid hyperplasia and high
circulating parathyroid hormone (PTH) levels is crucial in pre-
venting secondary hyperparathyroidism (SH) in renal failure.
In patients with chronic renal failure (CRF), parathy-Parathyroid gland enlargement and elevated levels of PTH are
roid hyperplasia, and enhanced synthesis and secretionmajor contributors to increase bone resorption, a feature of renal
osteodystrophy. of parathyroid hormone (PTH) characterize secondary
Methods. These studies assessed the efficacy of the 1,25(OH)2D3 hyperparathyroidism (SH) [1–4]. The enlargement of the
analog, 19-Nor-1,25(OH)2D2 (19-Nor), in the prevention (proto- parathyroid glands and high circulating levels of PTH [5]col I) and treatment (protocol II) of SH and renal osteodystrophy
are major contributors to increased bone resorption, ain uremic rats. In protocol I, normal and uremic rats were fed a
feature of renal osteodystrophy. Uremia, low calciumhigh phosphorus diet for 2 months; uremic rats were administered
intraperitoneal injections of either vehicle or 19-Nor (200 ng intake, high dietary phosphorus, and vitamin D deficiency
three times a week). In protocol II, normal and uremic rats are the main regulators of SH [6]. Although the mecha-
were fed a high phosphorus diet for 4 months; 2 months after
nisms by which these factors control PTH biosynthesisthe onset of uremia, rats were administered either intraperito-
and secretion are well known, optimal treatments areneal vehicle or 19-Nor (200 ng three times a week). Serum PTH
and bone histology were used to assess the degree of SH. still being developed.
Results. 19-Nor was effective in preventing (protocol I) and 1,25(OH)2D3 (1,25D) has been used in the treatment
suppressing (protocol II) the significant SH induced by uremia of SH because of its efficacy in suppressing PTH secre-and further enhanced by a high phosphorus diet. In protocol
tion and synthesis [7]. However, both hypercalcemia andI, bone histology in uremic controls showed a threefold increase
hyperphosphatemia, a result of increased intestinal cal-in the cancellous bone mass compared to normal rats. This
expansion in unmineralized bone was accompanied by 5-, 1.5-, cium and phosphorus absorption and bone-mineral re-
and 7-fold increases in eroded surface, mineralization lag time sorption, may develop in some patients, thus, this may
(MLT), and bone formation rate (BFR/BS), respectively. More- preclude 1,25D use in these uremic patients. In addition,over, cortical bone porosity in untreated uremic rats increased
1,25D-induced enhancement of serum calcium levels pro-267-fold compared to normal animals. 19-Nor ameliorated these
motes an elevated calcium-phosphate product increasingchanges in cancellous and cortical bone. In protocol II, the re-
ported indices worsened even further. In contrast, 2 months of the risk of vascular calcification especially in patients
19-Nor treatment improved bone histology by reducing cortical receiving calcium salts as phosphate binders [8, 9].
bone porosity, woven bone formation, MLT, and BFR/BS. Previous studies in our laboratory have demonstratedConclusion. In an experimental model of chronic renal fail-
that 19-Nor-1,25(OH)2D2 (19-Nor), a new analog ofure (CRF), 19-Nor prevents SH and ameliorates the histomor-
1,25(OH)2D3 (1,25D), suppresses PTH in uremic ratsphometric changes induced by uremia and high phosphorus
diet. In addition, 19-Nor suppresses serum PTH and improves with SH at doses which do not increase either serum
bone histology in uremic rats with established severe SH. Fur- calcium or phosphorus [10, 11]. The mechanisms respon-
sible for the decreased calcemic and phosphatemic activi-
ties of 19-Nor are not completely understood. Data fromKey words: renal osteodystrophy, vitamin D, bone histomorphometry.
our laboratory in parathyroidectomized rats fed either
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However, both promote bone differentiation of the osteo- 19-Nor (N 8) as in protocol I, except that the injections
were begun 2 months after the induction of renal failureblast phenotype, which is required for normal bone forma-
tion. Furthermore, 19-Nor is currently used in hemodial- and continued for an additional 2 months. For both pro-
tocols all rats received subcutaneous injections of a tetra-ysis patients as an alternative to 1,25D therapy [13].
1,25D not only potently stimulates bone resorption cycline derivative, demeclocycline (#D-614) (Sigma Chem-
ical Co., St. Louis, MO, USA), 20 mg/kg, 12 days beforebut also promotes bone formation. The effects of 1,25D
on osteoblasts and their precursors, which are multiple sacrifice. In addition, both 2- and 4-month uremic and
normal animals were injected subcutaneously with calceinand complex, include (1) decreasing the rate of cell pro-
liferation, while enhancing the process of mineralization; (#C-0875) (Sigma Chemical Co.), 10 mg/kg, 2 days before
sacrifice (10 days after the demeclocycline administration).(2) increasing both gene and protein expression of a num-
ber of matrix proteins, including type 1 collagen, osteo- At the end of each study, normal and uremic rats were
anesthetized and sacrificed by exsanguination. Arterialcalcin, and osteopontin; and (3) stimulating production
of the ectoenzyme alkaline phosphatase and the growth blood was drawn by aortic puncture for analytic determi-
nations. After sacrifice, tibiae were surgically removed,factors, transforming growth factor- (TGF-) and insu-
lin-like growth factor-1 (IGF-1), as well as the family of stripped of all muscle, and saved for histomorphometric
analysis of cancelleous and cortical bone.binding proteins that modulates the activity of the latter
molecule [14]. Studies in patients with CRF demon- All experimental protocols were approved by the Ani-
mal Studies Committee at Washington University Schoolstrated that, in some patients, the administration of
calcitriol induced adynamic bone disease [15]. Concern of Medicine.
that prolonged 19-Nor therapy might have negative side
Analytic determinationseffects on the bone metabolism of hemodialysis patients
led us to examine two markers of bone formation, alka- Plasma phosphorus and creatinine were determined
using an autoanalyzer (COBAS-MIRA Plus, Branch-line phosphatase and osteocalcin in MG-63 cells, an os-
teoblastic-like cell line [16]. These in vitro studies sug- burg, NJ, USA). Ionized calcium was measured by an
ionized calcium–specific electrode (Model ICA-1; Radi-gested that 19-Nor is as active as 1,25D in promoting
bone formation. ometer, Copenhagen, Denmark). Intact PTH levels were
measured by an immunoradiometric assay specific forIn the present studies, we examined the in vivo effects
of 19-Nor administration on bone. In our experimental rat intact PTH (Immutopics, San Clemente, CA, USA).
model of CFR, 19-Nor therapy not only prevents SH
Tetracycline derivative preparationand ameliorates the histomorphometric alterations in-
duced by uremia and high dietary phosphorus, but also Thirty minutes prior to injection, demeclocycline pow-
der was mixed with bacteriostatic water, stirred, andsuppresses serum PTH and improves bone histology in
uremic rats with established severe SH. adjusted for a pH between 7.2 and 7.4. Calcein powder
was slowly added to a sodium bicarbonate saline solution
and stirred until dissolved. This solution was filtered
METHODS
through a 0.2  millipore filter, mixed, and used for the
Experimental protocols injections.
Normal and uremic (5/6 nephrectomized) female
Bone histomorphometrySprague-Dawley rats, 8 to 10 weeks old and weighing
225 to 250 g, were studied. The 5/6 nephrectomy involved Immediately after removal of all muscles, tibiae were
fixed in 70% alcohol. The proximal portion and the mid-the ligation of several branches of the left renal artery
and excision of the right kidney. All animals were fed a dle third of the right tibiae were stained with Villanueva
stain, dehydrated in graded concentrations of ethanol,high phosphorus diet containing 0.9% phosphorus and
0.6% calcium, purchased from Dyets, Inc. (Bethlehem, defatted in acetone, and embedded in methyl methacry-
late (Fisher Scientific, Fairlaw, NJ, USA). LongitudinalPA, USA).
Protocol I. During the studies, normal rats (control sections of the proximal portion of the tibiae and cross
sections at the tibiofibular junctions of the tibial shaftsgroup) (N  9) received 100 L of propylene glycol as
vehicle, three times a week for 2 months. Immediately were cut to a thickness of 230 m using a low speed
metallurgic saw and then ground to thicknesses of 20 mafter the onset of renal failure, uremic rats received intra-
peritoneal injections of either 100L of propylene glycol (proximal portion of the tibiae) and 30 m (tibiofibular
junctions of the tibial shafts) for histomorphometric mea-as vehicle (N  8) or 19-Nor (200 ng) (N  9) three
times a week for 2 months. surement. Histomorphometry was done using a semiauto-
matic image analysis system (OsteoMeasure, Osteo-Protocol II. Normal rats (N  8) received 100 L of
propylene glycol as vehicle, three times a week for 4 Metrics, Inc., Decatur, GA, USA) linked to a microscope
equipped with transmitted and fluorescence light. Allmonths, uremic rats received either vehicle (N  8) or
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Table 1. Abbreviations of bone histomorphometric indices
Parameters Abbreviations
Cancellous bone
Total bone volume TBV/TV
Woven bone volume WB/TV
Eroded surface ES/BS
Mineralization lag time MLT
Bone formation rate (bone surface based) BFR/BS
Bone formation rate (bone area based) BFR/BV
Cortical bone
Total cross-sectional area TAr
Marrow area MaAr
Cortical bone width CtWi
Cortical bone area CtAr
Porosity area PoAr
Periosteal-bone formation rate Ps-BFR
Osteoid perimeter Ec-OPm
parameters were calculated according to the recommen-
dations of the Histomorphometry Nomenclature Com-
mittee of the American Society of Bone and Mineral
Research [17, 18]. Fig. 1. Experimental design. (A ) In protocol I, normal (N) and uremic
(U) rats underwent one of the following experimental protocols for 2The region of the proximal tibial metaphysis (PTM)
months: normal control  high phosphorus diet  vehicle (N  HP 
that was 1 to 4 mm distal to the growth plate–metaphyseal V), uremic control  high phosphorus diet  vehicle (U  HP  V),
uremic  high phosphorus diet  200 ng three times a week 19-Nor-junction was studied and the following measurements
1,25-(OH)2D2 (U  HP  19-Nor). (B ) In protocol II, normal (N) andtaken: total bone volume per total volume (TBV/TV)
uremic (U) rats underwent one of the following experimental protocols
(%), woven bone volume per total volume (WB/TV) for 4 months: normal control  high phosphorus diet  vehicle (N 
HPV), uremic control high phosphorus diet vehicle (UHP(%), eroded surface per unit of bone surface (ES/BS) (%),
V), uremic  high phosphorus diet  vehicle for the first 2 months ofmineralization lag time (MLT) (days), bone formation
study and during the last 2 months of study  200 ng three times a
rate per unit of bone volume (BFR/BV) (%/year), and week 19-Nor (U  HP  19-Nor).
bone formation rate per unit of bone surface (BFR/BS)
(m3/m2/day).
determined 2 and 4 months after the induction of renalCortical bone determinations included total cross sec-
insufficiency by 5/6 nephrectomy. Preliminary studiestional area (TAr) (mm2) cortical bone width (CtWi)
defined the nonhypercalcemic doses of the vitamin D(m), cortical bone area (CtAr) (mm2) marrow area
metabolite employed in the present protocols. Table 1(MaAr) (mm2), intracortical porosity area (PoAr) (mm2),
depicts the abbreviations for the bone histomorphome-
osteoid perimeter (OPm) (%), periosteal-bone forma- tric indices used in these analyses.
tion rate (Ps-BFR) (m/day/100) (Tables 1 and 3).
Study design
Statistics
Figure 1 depicts the experimental design for the proto-
For the biochemical analyses, analysis of variance cols for prevention and treatment studies. In protocol I,
(ANOVA) was employed to assess statistical differences after the onset of renal failure, the rats were divided into
between all experimental groups tested. Multiple com- two groups with similar serum creatinine levels. Uremic
parisons using the stringent Bonferroni test measured rats were injected intraperitoneally with vehicle or 19-
the statistical significance of the differences between ev- Nor, 3 times a week for 2 months. In protocol II, after
ery possible two-group comparisons. 2 months of renal failure, uremic rats were divided into
For bone histomorphometry, statistical analyses were two groups with similar serum creatinine levels. One
performed using SPSS for Windows (version 10.0, SPSS, group received 19-Nor and the other vehicle three times
Inc., Chicago, IL, USA). The Bonferroni post-hoc test a week for an additional 2-month period. Normal rats
was selected to analyze differences between groups. P (control group) received 100 L of propylene glycol as
vehicle three times a week for 2 or 4 months in both0.05 was considered significant.
protocols.
RESULTS Effects of 19-Nor on serum chemistry and
PTH secretionThe efficacy of 19-Nor in preventing (protocol I) and
treating (protocol II) high phosphorus-induced second- Table 2 shows the effects of 19-Nor treatment on se-
rum creatinine, ionized calcium, phosphorus, and PTHary hyperparathyroidism and bone damage in rats was
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Table 2. Serum chemistries
Protocol I Protocol II
Prevention Treatment
N  HP  V U  HP  V U  HP  19-Nor N  HP  V U  HP  V U  HP  19-Nor
2 months 2 months 2 months 4 months 4 months 4 months
(N  9) (N  8) (N  9) (N  8) (N  8) (N  8)
Creatinine mg/dL 0.910.07 1.970.35b 1.680.29 1.020.11 2.380.41b 1.620.22
Ionized calcium mg/dL 4.620.46 4.250.35 4.810.28 4.890.37 4.190.43 5.020.18
Phosphorus mg/dL 5.10.3 10.50.3a 7.80.2a,c 3.80.4 11.20.3a 7.20.2a,c
Parathyroid hormone pg/mL 214 908289a 4517c 237 2068354a 6719c
Normal (N) and uremic (U) rats underwent one of the following experimental protocols for either 2 or 4 months: normal control  high phosphorus diet  vehicle
(N  HP  V), uremic control  high phosphorus diet  vehicle (U  HP  V), uremic  HP diet  200 ng three times a week 19-Nor-1,25-(OH)2D2 (U  HP 
19-Nor). Values represent the meanSEM.
aP  0.01 vs. N  HP  V; bP  0.05 vs. N  HP  V; cP  0.01 vs. U  HP  V; dP  0.05 vs. U  HP  V
levels in uremic rats after either 2 or 4 months of renal mal rats very few double labels were observed at either
the periosteal or endocortical surfaces. In uremic un-failure. Serum creatinine increased in both 2- and 4-month
uremic animals fed high dietary phosphorus compared treated animals, much more bone, osteoid, double labels,
wide interlabeled width, diffuse labels, and bone erosionto normal controls. The elevation in serum creatinine
levels was lower after 2 and 4 months in uremic rats were seen. In contrast, in 19-Nor–treated rats, more bone
of lamellar structure was noted compared to the normaltreated with 19-Nor compared to untreated uremic ani-
mals. In addition, as indicated in Table 2, serum phospho- controls. Moreover, we observed less osteoid, double
labeling, intracortical porosity and bone erosion in ure-rus levels in uremic rats were reduced by 19-Nor adminis-
tration. As expected, treatment with the vitamin D analog mic rats receiving 19-Nor.
did not significantly increase ionized calcium compared
Effects of chronic renal failure and 19-Nor onto normal rats fed the same high phosphorus diet.
cancelleous and cortical bone (protocol IIUntreated uremic controls in both protocols I and II
at 4 months)had higher serum PTH levels than normal controls. In
contrast, 19-Nor not only prevented the increase in se- Table 3 shows the static and dynamic histomorphome-
rum PTH induced by high dietary phosphorus after 2 tric changes observed in the 4-month study. After 4
months of uremia, but also reduced the very high PTH months of CRF, the amount of woven bone was further
levels seen in the 4-month study. increased (↑43%), compared to the 2-month study. Ele-
vated bone turnover (BFR/BV) and prolonged MLT
Effects of CRF and 19-Nor on cancelleous and were also seen. Moreover, the total cross-sectional area
cortical bone (protocol I at 2 months) of tibiofibular junctions of the tibial shafts increased by
12%, the MaAr decreased by 22%, and the CtWi in-For the 2-month study, Table 3 shows the static and
dynamic histomorphometric changes in the PTM and creased by 17%. PoAr was also increased compared to
2-month uremic (169%) and age-matched normal ratsthe cross sections at the tibiofibular junctions of the tibial
shafts. After 2 months of renal failure, total bone mass (700-fold). Importantly, compared to the untreated ure-
mic group, rats receiving 2 months of 19-Nor treatmentincreased due mainly to increases in woven bone. MLT
increased by 48%, while eroded surface and bone forma- initiated 2 months after the onset of uremia had lower
ES/BS, MLT, and BFR/BV, 79%, 53%, and 88%, respec-tion rate increased by five- to sixfold. In the tibiofibular
junctions of the tibial shafts, intracortical porosity area tively. In the tibiofibular junctions of the tibial shafts,
porosity area, periosteal bone formation and endocorti-also markedly increased from 0.001  0.000 to 0.267 
0.01. In addition, both periosteal and endocortical bone cal bone formation decreased 96%, 33%, and 85% re-
spectively, in 19-Nor treated rats versus untreated uremicformation increased by at least 30-fold. Compared to the
uremic group, treatment with 19-Nor lowered WBV/TV controls.
The effects of 4 months of CRF and 19-Nor treatmentto that of normal controls. MLT, ES/BS and BFR/BS
were lowered by 45%, 74%, and 37%, respectively. In on both cancellous and cortical bone are showed in Fig-
ure 3 A and B, respectively. In uremic untreated rats,uremic rats receiving 19-Nor, PoAr, BFR of the perios-
teal and BFR of endocortical surfaces were lowered by more cancellous bone, double labels, osteoid, and ero-
sion were seen. The structure of the cortex was distorted96%, 46%, and 57%, respectively.
The effects of 2 months of CRF and preventive 19- and greater intracortical porosity was present. In con-
trast, 19-Nor–treated animals had less osteoid, doubleNor administration on both cancellous and cortical bone
are illustrated in Figure 2 A and B, respectively. In nor- labeling, intracortical porosity, and bone erosion.
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Table 3. Histomorphometric determinations of the proximal tibial methaphyses (PTM) and tibial shaft (TX)
Protocol I Protocol II
Prevention Treatment
N  HP  V U  HP  V U  HP  19-Nor N  HP  V U  HP  V U  HP  19-Nor
2 months 2 months 2 months 4 months 4 months 4 months
(N  9) (N  8) (N  9) (N  8) (N  8) (N  8)
PTM
TBV/TV % 14.53.5 46.330.6a 8.83.7a,b 8.02.7 59.528.5a 21.77.8a,b,c
WB/TV % 0.000.00 17.415.5 0.000.00 0.000.00 24.913.4 0.000.00
ES/BS % 3.20.8 16.63.6a 4.42.7b 7.91.7 20.97.7a 4.31.4a,b
MLT days 2.70.5 4.01.1a 2.20.7b N/A 5.53.3 2.60.9b
BFR/BS lm3/lm2/d 11.59.1 79.224.6a 49.611.8a 0.00.0a 14166a 26.29.7a,b,c
BFR/BV %/y 143111 620159a 635153a 0.00.0a 1782887a,c 22085a,b,c
TX
TAr mm2 4.70.2 5.00.2a 5.30.2a,b 5.20.3 5.60.3a 5.70.4a,d
MaAr mm2 0.80.1 0.90.3 1.00.2a 1.00.1 0.70.4a 1.00.1b
CtWi lm 74260 75977 76644 76440 885125a,c 81628a,d
CtAr mm2 3.90.2 3.80.3 4.30.2a,b 4.20.3 4.20.3a,c 4.70.3a,b,d
PoAr mm2 0.0010.000 0.2670.01a 0.010.03b 0.0010.000 0.720.43a,c 0.030.04a,b
Ps-BFR lm/d/100 2.92.8 91.161.4a 49.637.1b 2.13.8 111.259.3a 74.723.6
OPm % 0.440.80 48.124.7a 22.013.0a,b 11.54.4 64.826.2a 36.818.1a,b,d
For abbreviations, see Table 1. Normal (N) and uremic (U) rats underwent one of the following experimental protocols for either 2 or 4 months: normal control 
high phosphorus diet  vehicle (N  HP  V), uremic control  high phosphorus diet  vehicle (U  HP  V), uremic  HP diet  200 ng three times a week
19-Nor-1,25-(OH)2D2 (U  HP  19-Nor). Values represent the meanSD.
aP  0.01 vs. N  HP  V; bP  0.01 vs. U  HP  V; cP  0.01 vs. U  HP  V (2 months); dP  0.01 vs. U  HP  19-Nor (2 months)
DISCUSSION hyperphosphatemia in uremic rats [10]. Our results con-
firm that 19-Nor controls SH by reducing serum PTHThese studies assessed the effects of the 1,25D analog,
levels, with little effect on serum calcium and phosphorus19-Nor, in the prevention and treatment of high phos-
levels in uremic rats [16]. Moreover, recent studies inphorus-induced secondary hyperparathyroidism and bone
humans have reported a 60% reduction in PTH levelsdamage in a model of experimental uremia.
in hemodialysis patients treated with 19-Nor comparedWe first studied [protocol I (2 months)] the effect of
to those receiving placebo [13].19-Nor on the prevention of SH and bone pathology.
It is well known that vitamin D deficiency, an impor-Second, we studied [protocol II (4 months)] the ability
tant determinant of SH, is dangerous to the skeleton,of 19-Nor to reverse SH and correct the alterations in
particularly the cortical bone [20]. It is also well estab-bone histomorphometry. Clearly, after 2 months of ure-
lished that 1--hydroxyvitamin-D3 has a beneficial effectmia, treatment with the vitamin D analog ameliorated
on the histomorphometric changes seen in the bone ofthe increases in serum creatinine, phosphorus, and PTH
CRF patients [21, 22]. Moreover, early treatment withlevels. Importantly, 19-Nor did not increase ionized cal-
vitamin D during the development of renal failure cancium significantly above the levels seen in normal rats
prevent not only the biochemical changes but also thefed the same high phosphorus diet. However, a minor
histologic bone damage induced by SH in uremic patientsincrease in ionized calcium may also participate in the
[23, 24]. Clearly, improvements in PTH suppression andcorrection of secondary hyperparathyroidism between
bone histology were observed in adults and children withthe uremic groups.
renal failure who were treated with alfacalcidol [25, 26].The control of secondary hyperparathyroidism is an
Recent studies showed the efficacy of the combined ther-important goal in patients with CRF [19]. 19-Nor is cur-
apy with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxy-rently being used in the treatment of secondary hyper-
vitamin D3 on biochemical and histologic features ofparathyroidism because it suppresses serum PTH levels
without producing significant either hypercalcemia or renal osteodystrophy in rats with CRF [27]. Moreover,

Fig. 3. Effects of chronic renal failure (CRF) and 19-Nor-1,25(OH)2D2 (19-Nor) on cancelleous (A ) and cortical (B) bone (protocol II; 4 months).
Normal (N) and uremic (U) rats underwent one of the following experimental protocols: normal control  high phosphorus diet  vehicle for 4
months (left panels), uremic control  high phosphorus diet  vehicle for 4 months (middle panels), and uremic  HP diet  vehicle for the first
2 months of study and during the last 2 months of study  200 ng three times a week 19-Nor-1,25-(OH)2D2 (right panels). In uremic untreated
rats, more cancellous bone, double labels (arrow heads), osteoid and erosion (arrows) were seen (A). The structure of the cortex was distorted, with
elevated intracortical porosity (B). In contrast, in 19-Nor-treated animals there was less osteoid, double labeling, intracortical porosity, and bone
erosion. 20 mm, Villanueva-stained sections. Abbreviations are: T, trabeculae; M, marrow; O, osteoid; C, cortex; P, porosity. Magnification 	160.
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Fig. 2. Effects of chronic renal failure (CRF) and 19-Nor-1,25(OH)2D2 (19-Nor) on cancelleous (A ) and cortical (B ) bone (protocol I; 2 months).
Normal (N) and uremic (U) rats underwent one of the following experimental protocols for 2 months: normal control  high phosphorus diet 
vehicle (left panels), uremic control  high phosphorus diet  vehicle (middle panels), and uremic  high phosphorus diet  200 ng three times
a week 19-Nor-1,25-(OH)2D2 (right panels). Uremic animals had massive osteoid formation, wide interlabel width (arrow heads), bone erosion
(arrows) in the proximal tibial metaphysis (A) and had large porosity in the cortex (B). 19-Nor–treated rats had more cancellous bone compared
to normal rats, consisting of lamellar bone structure. Moreover, less osteoid, double labeling, intracortical porosity, and bone erosion was seen.
20 m, Villanueva-stained sections. Abbreviations are: T, trabeculae; M, marrow; O, osteoid; C, cortex; P, porosity. Magnification 	160.
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the effect of the combined administration of 24,25-dihy- CONCLUSION
droxyvitamin D3 and 1--hydroxyvitamin-D3 was studied 19-Nor was shown to improve mineralization and pre-
in patients with chronic renal insufficiency [28]. Finally, vent the formation of abnormal woven bone. Most im-
another vitamin D analog, 22-oxacalcitriol, has been portant, this vitamin D analog suppressed serum PTH
shown to significantly decrease serum PTH levels and levels without inducing low bone turnover [36].
These studies in rats with CRF demonstrate that 19-reverse abnormal bone resorption without induction of
Nor prevents secondary hyperparathyroidism and ame-adynamic bone disease in dogs with renal failure [29].
liorates the histomorphometric changes induced by ure-Because no long-term studies have evaluated the effi-
mia and high dietary phosphorus. In addition, 19-Norcacy of 19-Nor in preventing and treating bone disease
suppresses serum PTH and improves bone histology inin renal failure, we studied the effects of this compound
uremic rats with established severe secondary hyperpara-on reducing the bone structure modifications that are
thyroidism. Because of its ability to suppress PTH andinduced by CRF and further enhanced by high dietary
treat renal osteodystrophy in our experimental modelphosphorus in uremic rats.
of renal failure, 19-Nor could be considered a tool for
To assess the role of 19-Nor on bone in vivo, we per-
therapeutic intervention in secondary hyperparathyroid-
formed bone histomorphometry on rat tibiae from each ism in CRF. These results in uremic rats should be inter-
experimental condition. Two months of uremia induced preted with caution and cannot be extrapolated to pa-
significant histomorphometric changes of both the PTM tients with CRF. Further studies are critical to evaluate
and the cross sections of the tibiofibular junctions of the the role of 19-Nor in humans.
tibial shafts. The increase in total bone mass was due
mainly to an increase in woven bone. In addition, abnor- ACKNOWLEDGMENTS
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